Under construction – not a live service
Sign in
Taking people in FrancePhase 3

Myo-inositol with clomiphene to help women with polycystic ovary syndrome ovulate

Tests myo-inositol with clomiphene in women with polycystic ovary syndrome trying to conceive.

Plain-language title generated from the registry record
Registry title: Interest of Myo-inositol Supplementation in Women With Polycystic Ovarian Syndrome

Key facts

Where
Lille, FranceSee the site
Phase
Phase 3

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for women aged 18 to 35 with polycystic ovary syndrome (PCOS) who want to become pregnant and are starting clomiphene citrate to trigger ovulation.

Age
18 to 35 years
Sex
Women only
Disease stage
Polycystic ovary syndrome (PCOS) as defined by the Rotterdam criteria: at least two of three signs (many small follicles in the ovary, a cycle disorder, high male hormones).
Earlier treatment
Never treated with clomiphene citrate (CC), or an earlier CC treatment stopped more than 3 months ago.
Biomarker or test result
High antral follicle count (more than 19 per ovary) is one of the three signs of PCOS; at least two of the three are needed.

Main reasons for not taking part

  • Could not tolerate clomiphene citrate in an earlier treatment
  • BMI above 35
  • Another cause of missing or rare ovulation that needs its own treatment, such as high prolactin
  • Already pregnant when clomiphene citrate starts
  • Another male or female cause of reduced fertility

Read by machine on 12 November 2026.

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 35 years old?

Source: NCT03059173, who can take part

Where in France

  • CHU de Lille hôpital Jeanne de FlandreLille, FranceContact: Geoffroy Robin, MD, PhDTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
University Hospital, Lille
Trial code
NCT03059173
Record updated
22 April 2026
Original description
The main objective will be to check if MyoInositol (MYO) reduces the total resistance rate to Clomiphene Citrate (CC). For this, our study will be controlled, randomized and double blinded. It will include patients with PCOS (polycystic ovary syndrome, defined by the Rotterdam criteria) who wish to become pregnant and are eligible to simple ovulation induction by CC. Half of them will receive MYO + levomefolic acid (5-MTHF) in addition to the CC, while the other half will receive a placebo containing only 5-MTHF in addition to the CC. The MYO supplementation will be initiated at least one month before taking CC and will be continued throughout this treatment until pregnancy or before switching to another type of treatment for ovulation induction if no pregnancy is obtained after 6 ovulatory cycles.Read full original descriptionShow less

Interest of Myo-inositol Supplementation in Women With Polycystic Ovarian Syndrome During Induction of Ovulation With Clomiphene Citrate

The main objective will be to check if MyoInositol (MYO) reduces the total resistance rate to Clomiphene Citrate (CC). For this, our study will be controlled, randomized and double blinded. It will include patients with PCOS (polycystic ovary syndrome, defined by the Rotterdam criteria) who wish to become pregnant and are eligible to simple ovulation induction by CC. Half of them will receive MYO + levomefolic acid (5-MTHF) in addition to the CC, while the other half will receive a placebo containing only 5-MTHF in addition to the CC. The MYO supplementation will be initiated at least one month before taking CC and will be continued throughout this treatment until pregnancy or before switching to another type of treatment for ovulation induction if no pregnancy is obtained after 6 ovulatory cycles.

Inclusion: Wishing pregnancy,; Having PCOS defined by the Rotterdam criteria: high antral follicle count (AFC) (> 19 per ovary) and/or a disorder of the cycle and/or hyperandrogenism (at least two of the three criteria),; Having never been treated with CC (or previous treatment with CC interrupted for > 3 months); Having received complete information and having signed consent; Covered by social security.

Exclusion: Intolerance to CC in previous treatment,; History of ovarian drilling,; BMI > 35,; Other associated cause of oligoanovulation requiring specific treatment (eg., Hyperprolactinemia or functional hypothalamic anovulation),; Ongoing pregnancy at the time of CC initiation,; Other male or female cause of hypo-fertility,; Negative rubella serology.

ClinicalTrials.gov NCT03059173